Alligator Makes Advances In Pancreatic Cancer
Mitazalimab Succeeds In Interim Phase II Readout
The Swedish biotech is expecting intense discussions with prospective partners for mitazalimab, a couple of years after Janssen returned the rights to the CD40 agonist.
You may also be interested in...
Idogen Running Out Of Survival Options
With very little cash left in the bank, Idogen is weighing up its options including a reverse merger or liquidation.
Egetis Ends Takeover Talks To Focus On Emcitate
The Swedish firm has decided to pass on a bid from a proposed buyer which would have involved a healthy premium but “considerably undervalued” its long-term prospects.
BenevolentAI Slashes Jobs And Drug Programs
The UK firm, which uses artificial intelligence to discover and develop drugs, is hoping to save £45m by halving its workforce and trimming its pipeline.